ROLE OF NATRIUM-URETIC PEPTIDES IN THE DIAGNOSTICS OF HEART FAILURE
Abstract
Role of natrium-uretic peptides in the diagnostics of heart failure.
About the Authors
I. A. Sharoshina
Медицинский центр Управления делами Президента Российской Федерации, Москва
Russian Federation
Russian Federation
B. A. Sidorenko
Медицинский центр Управления делами Президента Российской Федерации, Москва
Russian Federation
Russian Federation
D. V. Preobrazhensky
Медицинский центр Управления делами Президента Российской Федерации, Москва
Russian Federation
Russian Federation
References
1. Yamamoto К., Burnett J. Superiority of Brain Natriuretic Peptide as a Hormonal Marker of Ventricular Systolic and Diastolic Dysfunction and Ventricular Hypertrophy.//Hypertension. 1996; Vol 28, N 6. P. 988-994.
2. Wei С.М., Heublein D.M., et al. Natriuretic peptide system in human heart failure. Circulation. 1993; 88: 1004-1009.
3. Cowie M., Pentson H., et al. A population survey of the incidence and aetiology of heart failure. Eur. Heart J. 1996; 17: 131 (abstr).
4. Omland Т., Aakvaag A., Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996; 76: 232-237.
5. Dao Q., Krishnaswamy P., et al. Utility of B-Type Natriuretic Peptide in the Diagnosis of Congestive Heart Failure in Urgent-Care Setting.//JACC. 2001. Vol 37, N 2. P. 379-385.
6. Dickstein K. Natriuretic peptide in detection of heart failure. Lancet 1998; 35: 3-4.
7. Maeda K., Takayoshi T., et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825-832.
8. Clerico A., Iervasi G., et al. Circulating levels of cardiac natri uretic peptide (AND and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998; 21: 170-179.
9. Tsutamoto Т., Wada A., et al. Attenuation of compensation of endogenonous cardiac natriuretic peptide system in chrinic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-516.
10. McDonagh Т.А., Robb S. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 13.
11. Davidson N.С., Naas A.A., et al. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996; 77: 828-831.
12. Nathisuwan S., Pharm. L., et al. A Review of Vasopeptidase Inhibitors: A New Modality in the Treatment of Hypertension and Chronic Heart Failure. Pharmacotherapy 2002; 22(1): 27-42.
13. Schiger J.A., Heublein D.M., et al. Presence of Dendroaspis natriuretic pep tide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin. Proс. 1999; 74: 126-130.
Review
For citations:
Sharoshina I.A., Sidorenko B.A., Preobrazhensky D.V. ROLE OF NATRIUM-URETIC PEPTIDES IN THE DIAGNOSTICS OF HEART FAILURE. Russian Journal of Cardiology. 2003;(3):81-86. (In Russ.)
Views:
309
Email this article 